References
- 1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl 2012; 2(4): 279-335.
- 2. Rossert JA, Wauters JP. Recommendation for the screening and management of patients with chronic kidney disease. Nephrol Dial Transplant 2002; 17(Suppl 1): 19-28.
- 3. Levin A. Anaemia and left ventricular hypertrophy in chronic kidney disease populations: A review of the current state ofknowledge. Kidney Int 2002; 61(Suppl 80): 35-8.
- 4. Stojimirović B, Petrović D, Obrenović R. Hipertrofija leve komore kod bolesnika na hemodijalizi: značaj anemije. Med Pregl 2007; LX (Supl 2): 155-9.
- 5. Petrović D, Miloradović V, Poskurica M, Stojimirović B. Dijagnostika i lečenje ishemijske bolesti srca kod bolesnika na hemodijalizi. Vojnosanit Pregl 2009; 66(11): 897-903.
- 6. Petrović D, Miloradović V, Poskurica M, Stojimirović B. Slabost srca bolesnika na hemodijalizi: procena i lečenje. Srp Arh Celok Lek 2011; 139(3-4): 248-55.
- 7. Petrović D, Trbojević-Stanković J, Stojanović-Marjanović V, Nikolić A, Miloradović V. Iznenadna srčana smrt bolesnika na hemodijalizi: procena rizika i prevencija. Ser J Exp Clin Res 2013; 14(1): 29-32.
- 8. Murray AM, Knopman DS, Tupper DE, Kane R. Cognitive impairment in hemodialysis patient is common. Nephrology 2006; 67(2): 216-23.
- 9. Murray AM, Pederson SL, Tupper DE, Hochhalter AK, Miller WA, Li Q, et al. Acute variation in cognitive function in hemodialysis patients: a cohort study with repeated measures. Am J Kidney Dis 2007; 50(2): 270-8.
- 10. National Kidney Foundation K/DOQI. Clinical Practice Guidelines for Anemia of Chronic Kidney Disease: Update 2000. Am J Kidney Dis 2001; 37(Suppl 1): 182-238.
- 11. Goodnough LT. The role of iron in erythropoiesis in the absence and presence of erythropoietin therapy. Nephrol Dial Transplant 2002; 17(Suppl 5): 14-18.
- 12. Cavill I. Iron and erithropoetin in renal disease. Nephrol Dial Transplant 2002; 17(Suppl 5): 19-23.
- 13. Hörl WH. Clinical Aspect of Iron Use in the Anemia of Kidney Disease. J Am Soc Nephrol 2007; 18(2): 382-93.
- 14. Wish J. Assessing Iron Status: Beyond Serum Ferritin and Transferrin Saturation. Clin J Am Soc Nephrol 2006; 1(Suppl 1): 4-8.
- 15. Drüke T. Hyporesponsiveness to recombinant human erythropoietin. Nephrol Dial Transplant 2001; 16 (Suppl 5): 50-5.
- 16. Good LT, Nemeth E, Ganz T. Detection, evaluation, and management of iron-restricted erythropoiesis. Blood 2010; 116(23): 4754-61.
- 17. Kiss Z, Ambrus C, Almasi C, Berta K, Deak G, Horonyi P, et al. Serum 25(OH)-cholecalciferol concentration is associated with hemoglobin level and erythropoetin resistance in patients on maintenance hemodialysis. Nephron Clin Pract 2011; 117(4): 373-8.
- 18. Icardi A, Paoletti E, De Nicola L, Russo R, Cozzolino M. Renal anemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation. Nephrol Dial Transplant 2013; 28(7): 1672-7.
- 19. Tattersal JE, Ward RA. Online haemodiafiltration: definition, dose quantification and safety revisited. Nephrol Dial Transplant 2013; 28(3): 542-50.
- 20. Canaud B, Barbieri C, Marcelli D, Bellocchio F, Bowry S, Mari F, et al. Optimal convection volume for improving patient outcomes in an international incident dialysis cohort treated with online hemodiafiltration. Kidney Int 2015; 88(5): 1108-16.
- 21. Marcelli D, Scholz C, Ponce P, Sousa T, Kopperschmidt P, Grassmann A, et al. High-Volume Postdilution Hemodiafiltration Is a Feasible Option in Rutine Clinical Practice. Artif Organs 2015; 39(2): 142-9.
- 22. De Roij van Zuijdewijn CLM, Chapdelaine I, Nube MJ, Blankestijn PJ, Bots ML, Konings CJAM, et al. Achieving high concentration volumes in postdilution online hemodiafiltration: a prospective multicenter study. Clin Kidney J 2017; 10(6): 804-12.
- 23. Rosati A, Ravaglia F, Panichi V. Improving Erythropoiesis Stimulating Agent Hyporesponsivenessin Hemodialysis Patients: The Role of Hepcidin and Hemodiafiltration Online. Blood Purif 2018; 45(1-3): 139-46.
- 24. Rossert JA, McClellan WM, Roger SD, et al. Contribution of anaemia to progression of renal disease : a debate. Nephrol Dial Transplant 2002; 17(Suppl 1): 60-6.
- 25. Tamura MK, Vittinghoff E, Yang J, Go AS, Seliger SL, Kusek JW, et al. Anemia and risk for cognitive decline in chronic kidney disease. BMC Nephrol 2016; 17(1): 13. doi:10.1186/s12882-016-0226-6.
- 26. Roger SD. Practical considerations for iron therapy in the management of anemia in patients with chronic kidney disease. Clin Kidney J 2017; 10(Suppl 1): 9-15.
- 27. Drüeke TB, Eckardt KU. Role of secondary hyperparatireoidism in erythropoetin resistance of chronic renal failure patients. Nephrol Dial Transplant 2002; 17(Suppl 5): 28-31.
- 28. Brancaccio D, Cozzolino M, Gallieni M. Hyperparathyroidism and Anemia in Uremic Subjects: A Combined Therapeutic Approach. J Am Soc Nephrol 2004; 15(Suppl 1): 21-4.
- 29. Jean G, Souberbielle JC, Chazot C. Vitamin D in Chronic Kidney Disease and Dialysis Patients. Nutrients 2017; 9(4): 328.
- 30. Stenvinkel P. The role of inflammation in the anaemia of end-stage renal disease. Nephrol Dial Transplant 2001; 16(Suppl 7): 36-40.
- 31. Akchurin OM, Kaskel F. Update on Inflammation in Chronic Kidney Disease. Blood Purif 2015; 39(1): 84-92.
- 32. Nassar GM, Fishbane S, Ayus JC. Occult infection of old non functioning arteriovenous grafts: A novel cause of erythropoietin resistance and chronic inflammation in hemodialysis patients. Kidney Int 2002; 61(Suppl 80): 49-54.
- 33. Chawla LS, Krishnan M. Causes and consequences of inflammation on anemia management in hemodialysis patients. Hemodialysis Int 2009; 13(2): 222-34.
- 34. De Oliveira Junior WV, de Paula Sabino, Figueiredo RC, Rios DRA. Inflammation and poor response to treatment with erythropoietin in chronic kidney disease. J Bras Nefrol 2015; 37(2): 255-63.
- 35. Panichi V, Rocchetti MT, Scatena A, Rosati A, Migliori M, Pizarelli F, et al. Long term variation of serum levels of uremic toxins in patient treated by post-dilution high volumen on-line hemodiafiltration in comparison to standard low-flux bicarbonate dialysis: results from the REDERET study. J Nephrol 2017; 30(4): 583-91.
- 36. Den Hoedt CH, Bots ML, Grooteman MPC, Der Weerd NC, Mazairac AHA, Penne EL, et al. Online hemodiafiltration reduces systemic inflammation compared to low-flux hemodialysis. Kidney Int 2014; 86(2): 423-32.
- 37. Panichi V, Scatena A, Rosati A, Giusti R, Ferro G, Malagnino E, et al. High-volume online hemodiafiltration improves erythropoiesis-stimulating agents (ESA) resistance in comparison with low-flux bicarbonate dialysis: results of the REDERT study. Nephrol Dial Transplant 2015; 30(4): 682-9.
- 38. Maduell F, Moreso F, Pons M, Ramos R, Mora-Macia J, Foraster A, et al. Desing and patient characteristics of ESHOL study, a Catalonian prospective randomized study. J Nephrol 2011; 24(2): 196-202.
- 39. Maduell F, Moreso F, Pons M, Ramos R, Mora-Macia J, Carreras J, et al. High-Efficiency Postdilution Online Hemodiafiltration Reduces All-Cause Mortality in Hemodialysis Patients. J Am Soc Nephrol 2013; 24(3): 487-97.
- 40. Peters SA, Bots ML, Canaud B, Davenport A, Grooteman MP, Locatelli F, et al. Haemodiafiltration and mortality in end-stage kidney disease patients: a pooled individual participant data analysis from four randomized controlled trials. Nephrol Dial Transplant 2016; 31(6): 978-84.